KYNB
KYNTRA BIO, INC.
Key Financials
Net Income
$183.5M
↑ 485.6%
Operating Income
$-45895000
↑ 69.5%
EPS (Diluted)
$45.37
↑ 9552.1%
Total Liabilities
$115.1M
↓ 71.1%
Revenue
$6.4M
↓ 78.3%
Total Assets
$119.6M
↓ 44.3%
Cash & Equivalents
$47.9M
↓ 5.2%
Shareholders' Equity
$-30038000.00
↑ 86.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 4 | 6/17/2026 | View on SEC |
| 8-K | 6/16/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 4 | 6/9/2026 | View on SEC |
| 8-K | 6/9/2026 | View on SEC |
| 4/A | 5/19/2026 | View on SEC |
| 4 | 5/18/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KYNB |
| Company Name | KYNTRA BIO, INC. |
| CIK | 921299 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 415-978-1200 |